Reporting owner · CIK 0001595855

Opaleye Management Inc.

SEC Form 4 history across 3 companies, 38 transactions and 14 filings.

10%Grace Therapeutics, Inc.
Open-market transaction mix100% buys38 buys · 0 sales

Available history · May 27, 2026 – Oct 16, 2026

Filings14Form 4 records
Buying$5.9M38 purchases
Selling$00 sales
Net value$5.9MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from available history.
Opaleye Management Inc. transactions · 20 per page
CompanyInsiderActivityDisclosed valueFiled (ET)
SLGLSol-Gel Technologies Ltd.
Opaleye Management Inc.10%P · buySEC filing ↗$98.4kView disclosure →
SLGLSol-Gel Technologies Ltd.
Opaleye Management Inc.10%P · buySEC filing ↗$108kView disclosure →
GRCEGrace Therapeutics, Inc.
Opaleye Management Inc.10%P · buySEC filing ↗$12.1kView disclosure →
GRCEGrace Therapeutics, Inc.
Opaleye Management Inc.10%P · buySEC filing ↗$19.6kView disclosure →
SLGLSol-Gel Technologies Ltd.
Opaleye Management Inc.10%P · buySEC filing ↗$212kView disclosure →
SLGLSol-Gel Technologies Ltd.
Opaleye Management Inc.10%P · buySEC filing ↗$32.6kView disclosure →
SLGLSol-Gel Technologies Ltd.
Opaleye Management Inc.10%P · buySEC filing ↗$233kView disclosure →
SLGLSol-Gel Technologies Ltd.
Opaleye Management Inc.10%P · buySEC filing ↗$144kView disclosure →
SLGLSol-Gel Technologies Ltd.
Opaleye Management Inc.10%P · buySEC filing ↗$63.8kView disclosure →
SLGLSol-Gel Technologies Ltd.
Opaleye Management Inc.10%P · buySEC filing ↗$14.9kView disclosure →
SLGLSol-Gel Technologies Ltd.
Opaleye Management Inc.10%P · buySEC filing ↗$341kView disclosure →
SLGLSol-Gel Technologies Ltd.
Opaleye Management Inc.10%P · buySEC filing ↗$344kView disclosure →
SLGLSol-Gel Technologies Ltd.
Opaleye Management Inc.10%P · buySEC filing ↗$1.37MView disclosure →
SLGLSol-Gel Technologies Ltd.
Opaleye Management Inc.10%P · buySEC filing ↗$713kView disclosure →
GRCEGrace Therapeutics, Inc.
Opaleye Management Inc.10%P · buySEC filing ↗$24.2kView disclosure →
ACOGAlpha Cognition Inc.
Opaleye Management Inc.10%P · buySEC filing ↗$416kView disclosure →
ACOGAlpha Cognition Inc.
Opaleye Management Inc.10%P · buySEC filing ↗$11.6kView disclosure →
ACOGAlpha Cognition Inc.
Opaleye Management Inc.10%P · buySEC filing ↗$6.65kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

buy at Grace Therapeutics, Inc. on Oct 16, 2026 valued at $68,758.

Review SEC filing
Latest buy

buy at Grace Therapeutics, Inc. on Oct 16, 2026 valued at $68,758.

Review SEC filing
Latest sale

No open-market insider sale is available.

Monthly open-market activity

Last 4 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
May 202630$434,713.77$0.00$434,713.77
Aug 202660$2,814,532.35$0.00$2,814,532.35
Sep 2026200$2,339,537.97$0.00$2,339,537.97
Oct 202690$289,679.67$0.00$289,679.67

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$154.7K
Median P/S size$43.5K
Direct0
Indirect38
Oct 16, 2026buy

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

17 observations · Aug 14, 2026 – Oct 16, 2026. Window ends at the latest available report, not today.

Selected observation · Oct 16, 20262,944,354 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 14, 20262,760,000Aug 19, 2026View transaction
Sep 8, 20262,769,393Sep 10, 2026View transaction
Sep 9, 20262,775,229Sep 10, 2026View transaction
Sep 21, 20262,850,000Sep 23, 2026View transaction
Sep 21, 20262,785,000Oct 1, 2026Amended transaction
Sep 23, 20262,855,318Sep 23, 2026View transaction
Sep 23, 20262,790,318Oct 1, 2026Amended transaction
Sep 29, 20262,798,167Oct 1, 2026View transaction
Oct 1, 20262,836,963Oct 5, 2026View transaction
Oct 2, 20262,856,963Oct 5, 2026View transaction
Oct 5, 20262,858,657Oct 5, 2026View transaction
Oct 8, 20262,860,734Oct 13, 2026View transaction
Oct 9, 20262,866,074Oct 13, 2026View transaction
Oct 12, 20262,873,289Oct 13, 2026View transaction
Oct 14, 20262,884,522Oct 17, 2026View transaction
Oct 15, 20262,908,007Oct 17, 2026View transaction
Oct 16, 20262,944,354Oct 17, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Opaleye Management Inc. Insider Activity FAQ

SEC Form 4 context

Who is Opaleye Management Inc.?

Opaleye Management Inc. is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001595855.

Which companies has Opaleye Management Inc. reported transactions for?

Grace Therapeutics, Inc., Alpha Cognition Inc., Sol-Gel Technologies Ltd., HARROW, INC., CODEXIS, INC.

When was Opaleye Management Inc.'s latest insider buy?

buy at Grace Therapeutics, Inc. on Oct 16, 2026 valued at $68,758.

When was Opaleye Management Inc.'s latest insider sale?

No open-market insider sale is available for this period.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.